Melphalan
- Generic Name
- Melphalan
- Brand Names
- Alkeran, Evomela, Phelinun, Pepaxti
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18Cl2N2O2
- CAS Number
- 148-82-3
- Unique Ingredient Identifier
- Q41OR9510P
- Background
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.
- Indication
Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
Melphalan is a component of HEPZATO KIT, a liver-directed therapy indicated for the treatment of adults with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.
- Associated Conditions
- Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2020-12-23
- Lead Sponsor
- University of Southampton
- Target Recruit Count
- 25
- Registration Number
- NCT00637767
- Locations
- 🇬🇧
Southampton General Hospital, Southampton, England, United Kingdom
🇬🇧Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust, Birmingham, England, United Kingdom
🇬🇧Saint Bartholomew's Hospital, London, England, United Kingdom
Anti-thymocyte Globulin and Melphalan in Treating Patients With Relapsed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 1
- Registration Number
- NCT00635024
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
MT2004-30: Tomotherapy for Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2008-02-25
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 23
- Registration Number
- NCT00623077
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis
- Conditions
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2011-05-10
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 27
- Registration Number
- NCT00621400
- Locations
- 🇫🇷
Hôpital Saint-Louis, Paris, France
🇫🇷CHRU d'Amiens, Amiens, France
🇫🇷CHRU de Lille, Lille, France
Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis
- Conditions
- Interventions
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 1
- Registration Number
- NCT00618540
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant
- Conditions
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2011-05-16
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 76
- Registration Number
- NCT00602706
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 306
- Registration Number
- NCT00602641
- Locations
- 🇺🇸
Illinois CancerCare-Peoria, Peoria, Illinois, United States
🇺🇸Methodist Medical Center of Illinois, Peoria, Illinois, United States
🇺🇸OSF Saint Francis Medical Center, Peoria, Illinois, United States
Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00591630
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
- Conditions
- Interventions
- Biological: anti-thymocyte globulinDrug: fludarabine phosphateDrug: cyclophosphamideDrug: etoposideDrug: melphalanDrug: sirolimusDrug: methotrexateDrug: tacrolimusProcedure: allogeneic hematopoietic stem cell transplantationProcedure: hematopoietic stem cell transplantationProcedure: nonmyeloablative allogeneic hematopoietic stem cell transplantationProcedure: peripheral blood stem cell transplantationRadiation: total-body irradiation
- First Posted Date
- 2008-01-09
- Last Posted Date
- 2014-09-10
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 32
- Registration Number
- NCT00589563
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Banner Good Samaritan Medical Center, Phoenix, Arizona, United States
Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2007-12-31
- Last Posted Date
- 2013-05-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 13
- Registration Number
- NCT00583622
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.